Literature DB >> 8634768

Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography.

R Teng1, T G Tensfeldt, T E Liston, G Foulds.   

Abstract

A simple, accurate and precise high-performance liquid chromatographic method was developed and validated for the determination of trovafloxacin, a new quinolone antibiotic, in serum and urine. Following solid-phase extraction, chromatographic separation was accomplished using a C18 column with a mobile phase consisting of 0.04 M H3PO4-acetonitrile-tetrabutylammonium hydroxide-0.005 M dibutyl amine phosphate (D-4) reagent (83:16.85:0.05:0.1, v/v), pH 3. Trovafloxacin and the internal standard (a methyl derivative of trovafloxacin) were detected by ultraviolet absorbance at 275 nm. The lower limit of quantification for trovafloxacin was 0.1 microgram/ml and the calibration curves were linear over a concentration range of 0.1 to 20.0 micrograms/ml (r2 = 0.9997). The average recoveries were greater than 70% for both trovafloxacin and internal standard. The intra-day and inter-day coefficients of variation were generally less than 5% in urine and serum over the concentration range of 0.1 to 20.0 micrograms/ml. Human serum samples could be stored for up to 12 months at -20 degrees C and urine samples could be stored up to 18 months at -80 degrees C.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8634768     DOI: 10.1016/0378-4347(95)00340-1

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  12 in total

1.  Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia.

Authors:  Keith M Olsen; Martha Gentry-Nielsen; Mei Yue; Mary U Snitily; Laurel C Preheim
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 2.  The use of gastrointestinal intubation studies for controlled release development.

Authors:  Steven C Sutton
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

3.  An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin.

Authors:  L Purkins; S D Oliver; S A Willavize
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

4.  Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.

Authors:  J S Bradley; G L Kearns; M D Reed; E V Capparelli; J Vincent
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.

Authors:  N R Cutler; J Vincent; S S Jhee; R Teng; T Wardle; G Lucas; L C Dogolo; J J Sramek
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS.

Authors:  M K Lacy; D P Nicolau; C H Nightingale; A Geffken; R Teng; J Vincent; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

7.  Dog colonoscopy model for predicting human colon absorption.

Authors:  Steven C Sutton; Loreen A Evans; Jay H Fortner; Jennifer M McCarthy; Kathy Sweeney
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

8.  Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.

Authors:  A J Fischman; J W Babich; A A Bonab; N M Alpert; J Vincent; R J Callahan; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.

Authors:  J Vincent; L Dogolo; B A Baris; S A Willavize; R Teng
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

10.  Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers.

Authors:  G Melnik; W H Schwesinger; R Teng; L C Dogolo; J Vincent
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.